📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-03 18:46
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
8 announcements match the current filters (relevance ≥ 5).
Hemo Organic Approves 9x Increase in Authorised Capital to ₹125 Cr; Pivots Business to Diamonds & Realty
Hemo Organic's Board has approved a massive increase in its Authorised Share Capital from ₹13.45 crore to ₹125.00 crore, subject to shareholder approval. The company is altering its Main Objects to pivot into diamond trading, manufacturing, and real estate development. A proposed fundraise was deferred to a subsequent board meeting. The company also appointed Ms. Pratibha Sharma as Company Secretary and Compliance Officer effective October 3, 2026.
Confidence: HIGH
What changedThe board approved a tenfold expansion in authorized share capital and added diamond processing/trading and real estate to its main MOA objects.
Why it mattersWith TTM revenue of just ₹1 crore and negative net worth, this signifies a potential total business transformation and major future equity dilution.
Previous Authorised Capital: Rs. 13,45,00,000/-Proposed Authorised Capital: Rs. 125,00,00,000/-New Authorised Shares: 12,50,00,000Authorised capital vs Market Cap: ~17.8x
📅 Short termMarket attention will focus on details of the deferred fundraising plan and whether a preferential issue or reverse merger structure is introduced.
📈 Long termComplete transformation into diamond and real estate sectors may reshape fundamentals, but raises execution and substantial dilution risks.
⚠ Risk flags
- Massive potential equity dilution given ₹125 crore authorized capital vs ₹7 crore market cap
- Entering completely unrelated industries (diamonds, real estate) with no prior track record
- Promoter holding is low at 16.85%
Key Highlights
Authorised Share Capital increased from ₹13.45 crore (1.345 crore shares) to ₹125.00 crore (12.5 crore shares of ₹10 each)
Proposed authorised capital of ₹125 crore represents nearly 18x the current market cap of ₹7 crore
Complete pivot of business objects to diamond trading/cutting/polishing and real estate development
Board deferred proposed fundraising to an upcoming meeting
Appointed Ms. Pratibha Sharma as Company Secretary & Compliance Officer w.e.f. October 3, 2026
👀 What to Watch
Track shareholder voting approvals on MOA alterations and the upcoming Board meeting announcement detailing the postponed fundraise structure and terms.
Hemo Organic Approves 9x Increase in Authorised Capital to ₹125 Cr; Pivots Business to Diamonds & Realty
Hemo Organic's Board has approved a massive increase in its Authorised Share Capital from ₹13.45 crore to ₹125.00 crore, subject to shareholder approval. The company is altering its Main Objects to pivot into diamond trading, manufacturing, and real estate development. A proposed fundraise was deferred to a subsequent board meeting. The company also appointed Ms. Pratibha Sharma as Company Secretary and Compliance Officer effective October 3, 2026.
Confidence: HIGH
What changedThe board approved a tenfold expansion in authorized share capital and added diamond processing/trading and real estate to its main MOA objects.
Why it mattersWith TTM revenue of just ₹1 crore and negative net worth, this signifies a potential total business transformation and major future equity dilution.
Previous Authorised Capital: Rs. 13,45,00,000/-Proposed Authorised Capital: Rs. 125,00,00,000/-New Authorised Shares: 12,50,00,000Authorised capital vs Market Cap: ~17.8x
📅 Short termMarket attention will focus on details of the deferred fundraising plan and whether a preferential issue or reverse merger structure is introduced.
📈 Long termComplete transformation into diamond and real estate sectors may reshape fundamentals, but raises execution and substantial dilution risks.
⚠ Risk flags
- Massive potential equity dilution given ₹125 crore authorized capital vs ₹7 crore market cap
- Entering completely unrelated industries (diamonds, real estate) with no prior track record
- Promoter holding is low at 16.85%
Key Highlights
Authorised Share Capital increased from ₹13.45 crore (1.345 crore shares) to ₹125.00 crore (12.5 crore shares of ₹10 each)
Proposed authorised capital of ₹125 crore represents nearly 18x the current market cap of ₹7 crore
Complete pivot of business objects to diamond trading/cutting/polishing and real estate development
Board deferred proposed fundraising to an upcoming meeting
Appointed Ms. Pratibha Sharma as Company Secretary & Compliance Officer w.e.f. October 3, 2026
👀 What to Watch
Track shareholder voting approvals on MOA alterations and the upcoming Board meeting announcement detailing the postponed fundraise structure and terms.
Hemo Organic allots 34 lakh shares via warrant conversion, raising Rs 3.19 cr
Hemo Organic Limited approved the allotment of 34,00,000 equity shares upon the conversion of warrants at Rs 12.50 per share. The company received the remaining 75% consideration amounting to Rs 3.19 crore from two non-promoter entities, Vacro Enterprises and Qmin Realities. This doubles the company's equity base from 34,65,900 shares to 68,65,900 shares, resulting in a ~49.5% dilution. The total inflow of Rs 3.19 crore represents approximately 45% of the company's existing market capitalization of Rs 7 crore.
Confidence: HIGH
What changedConversion of 34,00,000 convertible warrants into fully paid equity shares, doubling the company's share base.
Why it mattersProvides an equity cash infusion of Rs 3.19 crore (significant vs TTM revenue of Rs 1 cr), but leads to massive equity dilution of ~49.5% and hands nearly 50% ownership to two non-promoter entities.
Warrants converted: 34,00,000Issue price per share: Rs. 12.50/-Balance consideration received: Rs. 3,18,75,000/-Post-issue shares: 68,65,900Consideration received vs Market Cap: ~45.5%
📅 Short termWatch for listing and trading approvals from the stock exchange for the newly allotted 34 lakh equity shares, which could introduce floating supply.
📈 Long termWith two non-promoters now owning 49.52% collectively against promoter holding of under 17%, the company's ownership dynamics and business direction may undergo significant shifts.
⚠ Risk flags
- Severe equity dilution (~49.5% of post-issue equity)
- Significant concentration of equity (49.52%) across two private entities
- Weak underlying financials with negative operating profits and negative net worth
Key Highlights
34,00,000 equity shares allotted upon conversion of equal number of warrants at Rs 12.50 per share
Raised Rs 3,18,75,000 (Rs 3.19 cr) on receipt of 75% balance consideration
Vacro Enterprises and Qmin Realities each hold a 24.76% post-issue equity stake
Paid-up equity share capital expanded from 34,65,900 shares to 68,65,900 shares
👀 What to Watch
Track the deployment of the Rs 3.19 crore proceeds and monitor upcoming shareholding patterns to assess promoter dilution and any changes in management control.
Hemo Organic Allots 34 Lakh Equity Shares on Warrant Conversion; Equity Base Nearly Doubles
Hemo Organic Limited's Board has approved the allotment of 34,00,000 equity shares upon conversion of warrants at Rs 12.50 per share to non-promoter entities. The company received the remaining 75% consideration amounting to Rs 3,18,75,000 (Rs 3.19 Cr), bringing total proceeds from this issue to Rs 4.25 Cr. Following this conversion, the total paid-up equity shares expanded from 34,65,900 to 68,65,900, nearly doubling the share capital. The two allottees, Vacro Enterprises and Qmin Realities, now each hold a 24.76% stake in the expanded equity base.
Confidence: HIGH
What changedHemo Organic issued 34,00,000 new equity shares via warrant conversion, nearly doubling its outstanding share count to 68,65,900 shares.
Why it mattersThe company receives Rs 3.19 Cr in fresh cash, which is significant relative to its Rs 7 Cr market cap, but creates massive ~49.5% dilution for existing shareholders.
Shares allotted: 34,00,000Issue price per share: Rs. 12.50/-Balance consideration received: Rs. 3,18,75,000/-Post-allotment paid-up share count: 68,65,900Dilution to existing base: ~49.5%
📅 Short termThe infusion of Rs 3.19 Cr provides immediate liquidity to a micro-cap with minimal revenue, though the introduction of new floating supply could weigh on market prices once listed.
📈 Long termThe entry of two non-promoter shareholders with a combined 49.52% holding shifts the ownership structure substantially, which may signal a change in strategic direction or business control.
⚠ Risk flags
- Severe equity dilution of ~49.5% relative to the expanded share base
- Substantial shift in shareholding with two non-promoters controlling 49.52% of the company
- Weak underlying financials with negative operating profits and zero revenue in recent quarters
Key Highlights
Allotment of 34,00,000 equity shares upon conversion of warrants at Rs 12.50 per share
Receipt of remaining 75% warrant exercise consideration aggregating to Rs 3,18,75,000
Paid-up equity share capital increases from 34,65,900 shares to 68,65,900 shares
Two non-promoter entities (Vacro Enterprises and Qmin Realities) each acquire a 24.76% stake post-allotment
👀 What to Watch
Monitor the listing and trading approval from the stock exchange for the newly allotted shares, along with corporate governance disclosures given the high ownership concentration among the new non-promoter shareholders.
Promoters Sign SPAs to Offload 16.38% Stake (5,67,958 Shares) in Off-Market Deal
Promoters Dineshbhai Shanabhai Patel and Sonalben Dineshbhai Patel have entered into Share Purchase Agreements (SPAs) dated September 22, 2026, to sell 5,67,958 equity shares. This represents 16.38% of the company's equity capital, effectively offloading virtually all of the promoter group's reported 16.85% holding. The shares are being sold via off-market transactions to four buyers, including Ketanaben Jasani, Heema Makadia, V9BIZ Business Solution LLP, and Jasani Family Trust. The listed entity is not a party to the agreement, and no board seats or special rights are granted under the terms.
Confidence: HIGH
What changedPromoters agreed to sell an aggregate 16.38% equity stake in off-market transactions across four buyers.
Why it mattersThe promoter group holds 16.85% of the company, meaning this 16.38% transaction constitutes almost a full exit by the existing promoters in a microcap firm with ₹7 Cr market cap and nil operating revenue in recent quarters.
Total shares to be sold: 5,67,958Stake of existing equity capital: 16.38%Stake of fully diluted capital: 8.27%SPA execution date: 22nd September, 2026Promoter holding prior to transaction: 16.85%
📅 Short termMarket may react to near-complete promoter divestment; expect volatility given the micro-cap nature (₹7 Cr market cap) and lack of operational revenue.
📈 Long termSignifies a likely transition in ownership or entry of new strategic shareholders, crucial given the company's negative net worth and weak operating track record.
⚠ Risk flags
- Promoter near-total exit
- Severe financial distress (negative net worth, TTM losses of ₹1 Cr)
- Transaction price not disclosed in filing
Key Highlights
Promoters to sell 5,67,958 equity shares, representing 16.38% of existing equity share capital
Sale accounts for 8.27% of fully diluted share capital assuming full warrant conversion
Ketana Ben Jasani, Heema Makadia, and V9BIZ Business Solution LLP each acquiring 1,55,986 shares (4.50% each)
Jasani Family Trust acquiring an aggregate of 1,00,000 shares (2.88% total from both promoters)
SPAs executed on September 22, 2026, with consideration mutually agreed and no special/management rights granted
👀 What to Watch
Watch for subsequent shareholding pattern disclosures and regulatory filings to see if this near-complete promoter exit triggers a formal change in management or open offer requirements.
Hemo Organic Ltd Approves Q1 FY27 Un-audited Financial Results
Hemo Organic Ltd has approved its un-audited financial results for the quarter ended June 30, 2026, following a board meeting on July 15, 2026. The meeting lasted 75 minutes, concluding at 5:15 p.m. The filing confirms the submission of the Limited Review Report as per SEBI regulations. While the cover letter does not detail specific revenue or profit figures, it marks the formal reporting of the company's performance for the first quarter of the fiscal year.
Confidence: MEDIUM
What changedThe company has formally approved and submitted its financial performance report for the April-June 2026 quarter.
Why it mattersThis is a routine but essential regulatory requirement that provides transparency into the company's operational performance for the start of the new fiscal year.
Meeting Duration: 75 minutesQuarter Ended: 30th June, 20263-Month Price Return: 131.5%12-Month Price Return: 169.5%
📅 Short termNeutral. The market will likely wait for the detailed profit and loss statement to assess if the recent price rally is supported by fundamental growth.
📈 Long termLimited. This is a routine quarterly filing and does not indicate a structural change in the business model.
⚠ Risk flags
- High price volatility (131.5% in 3 months)
- Lack of specific financial data in the announcement extract
Key Highlights
Board meeting held on July 15, 2026, lasting from 04:00 p.m. to 05:15 p.m.
Approval of un-audited financial results for the quarter ended June 30, 2026.
Submission includes the mandatory Limited Review Report under Regulation 33 of SEBI LODR.
Stock has demonstrated a significant 131.5% price return over the last 3 months.
👀 What to Watch
Investors should examine the full financial tables to identify the drivers behind the recent 169.5% 12-month price return, as TTM revenue and PAT figures were not disclosed in the summary.
Hemo Organic Ltd Approves Un-audited Financial Results for Quarter Ended June 30, 2026
Hemo Organic Ltd's Board of Directors met on July 15, 2026, to approve the un-audited financial results for the first quarter of the fiscal year. The meeting lasted 75 minutes, concluding at 5:15 p.m. While the specific financial figures were not detailed in this outcome summary, the approval marks the completion of the regulatory review for the June 2026 quarter. Investors should note the stock's significant 169.5% price return over the last 12 months when evaluating the upcoming detailed P&L statement.
Confidence: HIGH
What changedThe company has completed its internal and board-level review of financial performance for the April-June 2026 period.
Why it mattersThis is a routine but essential regulatory requirement that provides transparency into the company's current fiscal health and operational performance.
Meeting Duration: 75 minutesQuarter Ended: 30th June, 202612-month Price Return: 169.5%3-month Price Return: 131.5%
📅 Short termThe stock may see volatility as the market digests the specific revenue and margin figures from the Q1 results.
📈 Long termLimited; this is a routine quarterly filing unless the detailed results show a structural shift in the trading business.
⚠ Risk flags
- High stock price volatility (131.5% in 3 months)
- Lack of disclosed TTM fundamentals in the current context
Key Highlights
Board approved un-audited financial results for the quarter ended June 30, 2026
The board meeting commenced at 04:00 p.m. and concluded at 05:15 p.m.
Stock has delivered a 131.5% price return over the last 3 months
The company is currently trading at a price of Rs 24.4
👀 What to Watch
Investors should examine the full financial tables and Limited Review Report to see if the company's revenue and profit growth justify the recent 169.5% annual price appreciation.
Hemo Organic Ltd Approves Q1 FY27 Un-audited Financial Results
Hemo Organic Ltd approved its un-audited financial results for the quarter ended June 30, 2026, during a board meeting held on July 15, 2026. The meeting was brief, lasting 75 minutes, and included the adoption of the Limited Review Report. While specific P&L figures were not detailed in the summary letter, this filing marks the official reporting of the company's performance for the first quarter of the fiscal year. Investors should monitor the detailed tables for revenue trends, especially given the stock's 169.5% price return over the last 12 months.
Confidence: MEDIUM
What changedThe company has completed its board-level review and approval of financial performance for the April-June 2026 period.
Why it mattersThis is a mandatory regulatory filing that provides the first data point for the company's performance in the new fiscal year, crucial for a stock with high recent price momentum.
Quarter ended: 30th June, 2026Meeting duration: 75 minutes3-month price return: 131.5%12-month price return: 169.5%
📅 Short termThe stock may see volatility as the market digests the specific revenue and profit figures contained in the full results document.
📈 Long termLimited structural significance unless the results demonstrate a sustainable turnaround or expansion in its trading and distribution operations.
⚠ Risk flags
- High price volatility (131.5% return in 3 months)
- Missing TTM financial benchmarks in the provided context
Key Highlights
Board meeting held on July 15, 2026, to approve un-audited results for the quarter ended June 30, 2026
Meeting commenced at 04:00 p.m. and concluded at 05:15 p.m.
Limited Review Report for the quarter was taken on record as per SEBI Regulation 33
Stock has shown a significant 3-month price return of 131.5% leading up to this announcement
👀 What to Watch
Investors should examine the detailed financial statements to identify the drivers behind the recent 131.5% three-month price surge and check for any operational improvements in the trading business.
